<DOC>
	<DOCNO>NCT01353222</DOCNO>
	<brief_summary>This study conduct examine survival , safety , magnitude immune response induce follow administration DN24-02 subject HER2+ urothelial carcinoma .</brief_summary>
	<brief_title>DN24-02 Adjuvant Therapy Subjects With High Risk HER2+ Urothelial Carcinoma</brief_title>
	<detailed_description>This multicenter , open-label , Phase 2 study . Subjects randomize either investigational product , DN24-02 , standard care . The purpose study compare length survival 2 group subject . Other purpose study learn safety DN24-02 , learn delay time urothelial cancer recurs , learn immune system respond treatment DN24-02 . All subject follow study remainder life .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Histopathologic evidence urothelial carcinoma high risk recurrence . Radical surgical resection perform ≤ 84 day ( 12 week ) prior registration . No evidence residual disease metastasis CT scan chest , abdomen pelvis obtain least 28 day follow surgical resection ≤ 28 day prior registration . HER2/neu tissue expression ≥ 1+ immunohistochemistry ( IHC ) . Available biopsy specimen primary tumor involve lymph node submit central pathology laboratory prior registration confirmation HER2/neu tissue expression . Last neoadjuvant chemotherapy treatment administer least 60 day prior registration . Left ventricular ejection fraction ≥ 50 % MUGA scan echocardiogram obtain least 28 day follow surgery ≤ 28 day prior registration . Women childbearing potential negative serum pregnancy test result ≤ 28 day prior registration agree breastfeed investigational treatment DN2402 28 day follow final infusion DN2402 . All male premenopausal female surgically sterilize agreed practice method birth control consider Investigator effective medically acceptable least 14 day prior registration , throughout treatment , 28 day follow final infusion DN2402 . Adequate hematologic , renal , liver function . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . A history stage III great nonurothelial cancer . Exceptions include : Subject basal squamous cell skin cancer adequately treat diseasefree time registration . Subjects diseasefree treatment ≥ 10 year time registration . A history stage I II nonurothelial cancer . Exceptions include : Subjects diseasefree treatment ≥ 3 year time registration ; subject incidental prostate cancer diagnose time cystoprostatectomy ; subject basal squamous cell skin cancer . Partial cystectomy set bladder cancer primary tumor . Partial nephrectomy set renal pelvis primary tumor . Adjuvant systemic therapy urothelial prostatic carcinoma follow surgical resection . Adjuvant radiation therapy urothelial prostatic carcinoma follow surgical resection . Incidental prostate cancer detectable postoperative ( radical cystoprostatectomy ) PSA level ≤ 28 day prior registration . Any major surgery ( e.g. , surgery require general anesthesia ) ≤ 28 day prior registration . Systemic treatment investigational clinical trial ≤ 28 day prior registration . Systemic glucocorticoid immunosuppressive therapy use ≤ 28 day prior registration . Any infection require parenteral antibiotic therapy cause fever ( i.e. , temperature &gt; 100.5°F &gt; 38.1°C ) ≤ 7 day prior registration . A history allergic reaction attribute compound similar chemical biologic composition DN2402 GMCSF . Any medical intervention , condition , circumstance , opinion Investigator Dendreon Medical Monitor , could compromise adherence study requirement otherwise compromise study 's objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Renal pelvis cancer</keyword>
	<keyword>Ureteral cancer</keyword>
	<keyword>Urethral cancer</keyword>
	<keyword>Bladder</keyword>
	<keyword>Renal pelvis</keyword>
	<keyword>Ureter</keyword>
	<keyword>Urethra</keyword>
	<keyword>Immune therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Dendritic cell</keyword>
	<keyword>Antigen-presenting cell</keyword>
	<keyword>Antigen present cell</keyword>
	<keyword>Cancer vaccine</keyword>
	<keyword>Urothelial carcinoma</keyword>
	<keyword>Urothelial neoplasm</keyword>
	<keyword>Neoplasms site</keyword>
	<keyword>Neoplasms</keyword>
</DOC>